In contrast, Song et al. have not yet validated the pathway of action of CDKN2B-AS1, and they also suggested that the effect of CDKN2B-AS1 on LC cells may not only be through the let-7c-5p/NAP1L1 axis. The gene discussed is NAP1L1; the disease is laryngotracheoesophageal cleft.